Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HUTCHMED (China) ( (HK:0013) ) has provided an update.
HUTCHMED has appointed Professor Tan Shao Weng, Daniel as an Independent Non-executive Director and a member of its Technical Committee. Professor Tan brings over 20 years of oncology experience, particularly in thoracic, head, and neck malignancies, and drug development. His expertise in targeted therapies and clinical oncology is expected to bolster HUTCHMED’s strategic growth and innovation in cancer drug development. This appointment reflects HUTCHMED’s ongoing commitment to enhancing its leadership team with experienced professionals to drive forward its mission in the biopharmaceutical industry.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought drug candidates from in-house discovery to patients worldwide, with its first three medicines marketed in China and one approved globally, including in the US, Europe, and Japan.
Learn more about 0013 stock on TipRanks’ Stock Analysis page.